Atelerix

Encapsulated human cells to revolutionise cell research

Atelerix was the first Northern Accelerator spin-out, with CEO Dr Mick McLean recruited through the project’s ‘Execs into Business’ programme.

Atelerix has a transformative technology that offers the safe storage and transport of viable cells, including stem cells and cell-based assays, at ambient temperatures, which overcomes the barriers and limitations of the current need for cryo-shipping.

This breakthrough, a patented invention, provides dramatic improvements to an everyday process in a rapidly growing market.

The shipping of cells from one location to another for clinical and research use is a widespread and everyday practice, so there are many potential commercial applications for the technology, including:

  • Businesses selling cells
  • Discovery and testing of new drugs
  • Developing cell therapies
  • Storing stem cells
Download Full Case Study

Having worked together for two years as CEO and Chief Scientist, Mick and I have successfully moved the company through the stages of business planning, company set-up and product development.


Professor Che Connon
Founder Academic

Understanding both the technology and its commercial potential is essential for the translation of great science into an exciting business opportunity


Dr Mick McLean
CEO

Support Received from Northern Accelerator

‘Execs into Business’ attracts talented business leaders to the innovative commercial opportunities created and developed in the North East’s universities. Experienced life sciences business leader Dr Mick McLean was brought in to work alongside the founder academics.

With Mick’s guidance, the company produced a viable business plan and raised seed capital investment to take the company forward.

Prof. Che Connon said: “Having worked together for two years as CEO and Chief Scientist, Mick and I have successfully moved the company through the stages of business planning, company set-up and product development.”

Going from Strength to Strength

In May 2019 Atelerix announced they’d closed a second round of funding of £700,000 to accelerate development of its products to market. The follow-on investment will be used to grow the team, increase revenues and expand the business.

Dr McLean commented: “We’re delighted with the success of this fully subscribed funding round. We’ve witnessed a lot of excitement for our products and this latest investment will allow us to grow the business faster and reach new markets.”

Timeline

  • Medical Research Council Grant

    2009

    Medical Research Council grant on stem cell delivery to ocular surface

  • New Scientific Observations

    2010

    Observation that cells were quiescent within hydrogel

  • New I.P. filed

    2011

    Intellectual Property filed for transport of cells in hydrogels

  • Further development thanks to BBSRC BRIC grant

    2013

  • DSTL grant

    2015

  • CEO Dr Mick McLean recruited

    2016

    Applied to Northern Accelerator to recruit CEO Dr Mick McLean

  • Spun out as Atelerix Ltd

    2017

    Co-founded and spun out Atelerix Ltd

  • UK Innovation & Science Seed Fund

    2018

    Raised £425,000 in a seed investment round led by specialist investor, UK Innovation & Science Seed Fund (UKI2S0).